TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30527329

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg tablets
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Raltegravir chewable tablets
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Raltegravir oral granules
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Raltegravir (all formulations)
Number of subjects: 153
Study: 30527497

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Vivostat) applied intraoperatively to the anastomosis
Number of subjects: 15
Study: 30527774

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-Molecular-Weight Heparin
Number of subjects: 0
Study: 30527797

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 11006

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 11006
Study: 30528561

Group type: EXPERIMENTAL
Intervention: tazobactam/ceftolozane 1.5 g (tazobactam 0.5 g/ceftolozane 1 g) plus metronidazole 500 mg intravenously every 8 h for 60 min for 4-14 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: tazobactam/ceftolozane plus metronidazole
Number of subjects: 100
Study: 30528620

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary interventions (PCI) for coronary bifurcations
Number of subjects: 5036

Group type: EXPERIMENTAL
Intervention: Independent predictors of MACE
Number of subjects: 5036
Study: 30528623

Group type: EXPERIMENTAL
Intervention: us-TnI < 1 ng/L directly on admission
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: us-TnI < 2 ng/L and 0/1h delta < 1 ng/L
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: us-TnI ≥ 25 ng/L on admission or 0/1h delta ≥ 6 ng/L
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: One-year rate of death or MI
Number of subjects: 1534
Study: 30529029

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir super-boosting with additional ritonavir (one-to-one ratio) during rifampicin treatment
Number of subjects: 96

Group type: COMPARATOR
Intervention: Lopinavir-ritonavir without rifampicin
Number of subjects: 96
Study: 30529085

Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD (52-mg, 20 mcg/d initial release)
Number of subjects: 20
Study: 30529112

Group type: EXPERIMENTAL
Intervention: Near-syncope
Number of subjects: 3581

Group type: COMPARATOR
Intervention: Syncope
Number of subjects: 3581
Study: 30529597

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus erlotinib
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus gefitinib
Number of subjects: 19
Study: 30529905

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) for 8 or 12 weeks
Number of subjects: 1819

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P)
Number of subjects: 1819
Study: 30530460

Group type: EXPERIMENTAL
Intervention: Web-based PAJ intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study: 30530461

Group type: EXPERIMENTAL
Intervention: Computer-aided telephone support intervention
Number of subjects: 377

Group type: COMPARATOR
Intervention: Usual care enhanced by periodic assessments
Number of subjects: 377
Study: 30530463

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data collection form focusing on airway management and hemodynamic management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scoring system for peri-intubation complications
Number of subjects: 0
Study: 30530477

Group type: EXPERIMENTAL
Intervention: Arabin cervical pessary
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard treatment (no pessary)
Number of subjects: 500
Study: 30530721

Group type: EXPERIMENTAL
Intervention: Daily oral therapy with tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 52
Study: 30530925

Group type: EXPERIMENTAL
Intervention: 600 mg efavirenz once daily during the third trimester (3T)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 600 mg efavirenz once daily during the second trimester (2T)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 600 mg efavirenz once daily postpartum (PP)
Number of subjects: 42
Study: 30530985

Group type: EXPERIMENTAL
Intervention: Oral d3-l-carnitine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chronic l-carnitine supplementation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fecal metabolic transformation studies
Number of subjects: 72
Study: 30531015

Group type: EXPERIMENTAL
Intervention: Intrathecal injection of Wharton's jelly-derived mesenchymal stem cells (average dose of 0.42 × 10^6 cells)
Number of subjects: 43
Study: 30531219

Group type: EXPERIMENTAL
Intervention: Child Induction Behavioral Assessment
Number of subjects: 384
Study: 30531385

Group type: EXPERIMENTAL
Intervention: Highly challenging gait and balance training for 10 weeks
Number of subjects: 47
Study: 30531561

Group type: EXPERIMENTAL
Intervention: Miscarriage
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Early pregnancy loss
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Spontaneous abortion
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Early pregnancy failure
Number of subjects: 145
Study: 30531565

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52-mg intrauterine system (IUS)
Number of subjects: 1751
Study: 30531573

Group type: EXPERIMENTAL
Intervention: Transcervical ablation
Number of subjects: 147
Study: 30532779

Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 43
Study: 30534007

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg or 20 mg, bodyweight-adjusted, single-dose)
Number of subjects: 59
Study: 30534008

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (tablet and oral suspension)
Number of subjects: 59
Study: 30534152

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 32
Study: 30534187

Group type: EXPERIMENTAL
Intervention: Fish oil omega-3 (3.17 g per day; eicosapentaenoic acid 2.15 g; docosahexaenoic acid 1.02 g)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Soybean oil
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Fish oil omega-3
Number of subjects: 282
Study: 30534341

Group type: EXPERIMENTAL
Intervention: TRACK questionnaire (Portuguese version)
Number of subjects: 299
Study: 30534340

Group type: EXPERIMENTAL
Intervention: House dust from allergic subjects
Number of subjects: 50

Group type: COMPARATOR
Intervention: House dust from non-allergic subjects
Number of subjects: 50
Study: 30534374

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg once daily
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 30535053

Group type: EXPERIMENTAL
Intervention: Stepped care models that integrate comorbidities, mainly via transdiagnostic self-management support, interprofessional collaboration, and digital approaches for treatment, monitoring, and communication.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Stepped care models targeting depressive disorders and other comorbid conditions.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Stepped care models in primary care.
Number of subjects: 39
Study: 30535067

Group type: EXPERIMENTAL
Intervention: Polygenic risk score
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Cognition pathways
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Cognition-related pathways
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Reciprocal causation
Number of subjects: 1313
Study: 30535087

Group type: EXPERIMENTAL
Intervention: Highest quartile of plasma TMAO concentration
Number of subjects: 1718

Group type: EXPERIMENTAL
Intervention: Each SD increment of ln-transformed plasma TMAO
Number of subjects: 1718
Study: 30535190

Group type: EXPERIMENTAL
Intervention: Ceftaroline 600 mg as a 1 h intravenous infusion
Number of subjects: 9
Study: 30535367

Group type: EXPERIMENTAL
Intervention: Ottawa AF cardioversion protocol (OAFCP)
Number of subjects: 889

Group type: COMPARATOR
Intervention: Standard cardioversion protocol (Phase I)
Number of subjects: 889
Study: 30535387

Group type: EXPERIMENTAL
Intervention: IBDoc home-based fecal calprotectin (FC) measuring test
Number of subjects: 61
Study: 30535795

Group type: EXPERIMENTAL
Intervention: Rice intake
Number of subjects: 45411

Group type: EXPERIMENTAL
Intervention: Replacing rice with noodles
Number of subjects: 45411

Group type: EXPERIMENTAL
Intervention: Replacing rice with red meat
Number of subjects: 45411

Group type: EXPERIMENTAL
Intervention: Replacing rice with poultry
Number of subjects: 45411

Group type: EXPERIMENTAL
Intervention: Replacing rice with white bread
Number of subjects: 45411

Group type: EXPERIMENTAL
Intervention: Replacing rice with wholemeal bread
Number of subjects: 45411
Study: 30536725

Group type: EXPERIMENTAL
Intervention: G-AgP
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: CP
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Gingivitis
Number of subjects: 87

Group type: COMPARATOR
Intervention: Healthy
Number of subjects: 87
Study: 30536810

Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 0
Study: 30536931

Group type: EXPERIMENTAL
Intervention: Boston Scientific LATITUDE RPM system
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: RPM preference
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: In-clinic follow-up preference
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Higher education, employment, new LATITUDE model
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease
Number of subjects: 300
Study: 30537010

Group type: EXPERIMENTAL
Intervention: Donor TLR9 rs352139 AG/GG carriers
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Combined effects of donor CYP3A5 rs776746 and donor TLR9 rs352139 genotypes
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: AG/GG patients
Number of subjects: 297
Study: 30537170

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) with diabetes remission
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) without diabetes remission
Number of subjects: 144

Group type: COMPARATOR
Intervention: Non-operated controls
Number of subjects: 144
Study: 30537529

Group type: EXPERIMENTAL
Intervention: Sirolimus (loading dose of 1.8 mg/m)
Number of subjects: 3
Study: 30537545

Group type: EXPERIMENTAL
Intervention: 2000 μg vitamin D oral bolus
Number of subjects: 0
Study: 30537548

Group type: EXPERIMENTAL
Intervention: Portal vein embolization (PVE)
Number of subjects: 128

Group type: COMPARATOR
Intervention: No portal vein embolization (NoPVE)
Number of subjects: 128
Study: 30537877

Group type: EXPERIMENTAL
Intervention: Interactions with biological and nonbiological network members regarding risk information and management strategies.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactions with nonbiological network members.
Number of subjects: 0
Study: 30537968

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) gel for 1 hour daily for 3 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) gel
Number of subjects: 58
Study: 30537991

Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 179

Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 179
Study: 30538057

Group type: EXPERIMENTAL
Intervention: Aspirin/rivaroxaban co-therapy
Number of subjects: 9954

Group type: EXPERIMENTAL
Intervention: COMPASS-Like patients
Number of subjects: 9954

Group type: EXPERIMENTAL
Intervention: COMPASS-Excluded patients
Number of subjects: 9954

Group type: EXPERIMENTAL
Intervention: COMPASS enrichment criteria
Number of subjects: 9954
Study: 30538102

Group type: EXPERIMENTAL
Intervention: Wide-field OCTA
Number of subjects: 88
Study: 30538161

Group type: EXPERIMENTAL
Intervention: 10-hour E-test approach
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard routine methods
Number of subjects: 28
Study: 30538817

Group type: EXPERIMENTAL
Intervention: Anifrolumab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30538854

Group type: EXPERIMENTAL
Intervention: TPRK (Transepithelial Photorefractive Keratectomy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: AAPRK (Alcohol-Assisted Photorefractive Keratectomy)
Number of subjects: 100
Study: 30538968

Group type: EXPERIMENTAL
Intervention: Ad:MG1 oncolytic vaccination strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ad vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MG1 vaccine
Number of subjects: 0
Study: 30538975

Group type: EXPERIMENTAL
Intervention: Resuscitation with the placental circulation intact
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cord milking
Number of subjects: 0
Study: 30539362

Group type: EXPERIMENTAL
Intervention: Lanadelumab
Number of subjects: 0
Study: 30539492

Group type: COMPARATOR
Intervention: Locoregional treatment (LRT) including radiotherapy, surgery, or both
Number of subjects: 4276

Group type: COMPARATOR
Intervention: Locoregional treatment (LRT)
Number of subjects: 4276
Study: 30539524

Group type: EXPERIMENTAL
Intervention: EndoBarrier™ implantation
Number of subjects: 10
Study: 30540612

Group type: COMPARATOR
Intervention: Prefrail patients
Number of subjects: 133

Group type: COMPARATOR
Intervention: Frail patients
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Nonfrail patients
Number of subjects: 133
Study: 30540645

Group type: EXPERIMENTAL
Intervention: ST-2 levels greater than 54 ng/ml
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: BNP levels greater than 567 pg/ml
Number of subjects: 121

Group type: COMPARATOR
Intervention: Serum ST-2 levels in diabetic patients
Number of subjects: 121

Group type: COMPARATOR
Intervention: BNP levels in HFrEF vs HFpEF
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Correlation between ST-2 and BNP in diabetic patients
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Correlation between ST-2 and left ventricular stiffness in diabetic patients
Number of subjects: 121
Study: 30540648

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 13980
Study: 30540702

Group type: EXPERIMENTAL
Intervention: Analytic focused health information
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Emotion focused health information
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both analytic and emotional information
Number of subjects: 52
Study: 30541333

Group type: EXPERIMENTAL
Intervention: LifeCourse (LC) program delivered by community health workers (CHWs) with standardized monthly 1-hour home visits based on palliative care guidelines and motivational interviewing.
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: LifeCourse (LC) program
Number of subjects: 903

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 903
Study: 30541456

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 431

Group type: COMPARATOR
Intervention: Non-black race
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 431
Study: 30541457

Group type: EXPERIMENTAL
Intervention: Virtual histology intravascular ultrasound (VH-IVUS) assessment of plaque composition and characteristics
Number of subjects: 175
Study: 30541505

Group type: EXPERIMENTAL
Intervention: Point-of-care testing for procalcitonin (PCT) using 0.5 ml of whole blood; results available within 20 minutes.
Number of subjects: 126
Study: 30541560

Group type: EXPERIMENTAL
Intervention: Ultrasound during antenatal care (ANC)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Communication strategies (referral card, directions, expectations)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Barriers to attending referrals
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Ultrasound screening at ANC
Number of subjects: 700
Study: 30541571

Group type: EXPERIMENTAL
Intervention: Turner Syndrome
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Turner Syndrome with coarctation
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Turner Syndrome without coarctation
Number of subjects: 57
Study: 30541757

Group type: EXPERIMENTAL
Intervention: Morning surgery (8:00 to 11:00)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Afternoon surgery (14:00 to 17:00)
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Both groups (morning and afternoon)
Number of subjects: 630
Study: 30542286

Group type: EXPERIMENTAL
Intervention: Low-dose azacitidine (AZA) in combination with PPARγ agonist pioglitazone (PGZ)
Number of subjects: 0
Study: 30542289

Group type: EXPERIMENTAL
Intervention: Non-periodized (NP) resistance training
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Daily undulating periodization (DUP) resistance training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study: 30542319

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30542322

Group type: EXPERIMENTAL
Intervention: AMH measured using Elecsys® AMH automated assay
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AMH measured at the moment of LH rise
Number of subjects: 22
Study: 30542377

Group type: EXPERIMENTAL
Intervention: Combination of everolimus, lapatinib, and capecitabine
Number of subjects: 19
Study: 30542622

Group type: EXPERIMENTAL
Intervention: Dalteparin sodium (initial dose of 5000 IU, adjustable by 500 or 1000 IU increments)
Number of subjects: 152
Study: 30542662

Group type: EXPERIMENTAL
Intervention: Screening, prevention and care for tuberculosis and HIV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening, prevention and care for tuberculosis and HIV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30543050

Group type: EXPERIMENTAL
Intervention: Gastrin-releasing peptide receptor antagonist
Number of subjects: 0
Study: 30543347

Group type: EXPERIMENTAL
Intervention: Alpelisib 400 mg once daily plus fulvestrant 500 mg
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Alpelisib 300 to 400 mg once daily plus fulvestrant
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Alpelisib 300 mg once daily plus fulvestrant
Number of subjects: 87
Study: 30543456

Group type: EXPERIMENTAL
Intervention: Participants with interstitial lung abnormalities (ILA) in COPDGene
Number of subjects: 7923

Group type: EXPERIMENTAL
Intervention: Participants with interstitial lung abnormalities (ILA) in ECLIPSE
Number of subjects: 7923

Group type: EXPERIMENTAL
Intervention: Participants with interstitial lung abnormalities (ILA) in FHS
Number of subjects: 7923

Group type: EXPERIMENTAL
Intervention: Patients with idiopathic pulmonary fibrosis (IPF)
Number of subjects: 7923

Group type: EXPERIMENTAL
Intervention: Research participants with ILA
Number of subjects: 7923
Study: 30543557

Group type: EXPERIMENTAL
Intervention: Elective minor abdominal surgery
Number of subjects: 60
Study: 30544060

Group type: EXPERIMENTAL
Intervention: Upfront DPYD-guided dose individualisation with initial dose reduction of 25% or 50% based on DPYD variants screening.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No DPYD screening (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upfront DPYD-guided dose individualisation.
Number of subjects: 0
Study: 30544235

Group type: EXPERIMENTAL
Intervention: Women with PCOS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study: 30545622

Group type: EXPERIMENTAL
Intervention: hs-cTnT-based strategies
Number of subjects: 3696

Group type: EXPERIMENTAL
Intervention: hs-cTnI-based strategies
Number of subjects: 3696

Group type: EXPERIMENTAL
Intervention: LoD-algorithm
Number of subjects: 3696

Group type: COMPARATOR
Intervention: Dual-marker approach
Number of subjects: 3696

Group type: COMPARATOR
Intervention: NICE-algorithm using hs-cTnI
Number of subjects: 3696
Study: 30545672

Group type: EXPERIMENTAL
Intervention: Serum uric acid (SUA) levels
Number of subjects: 17913
Study: 30545809

Group type: EXPERIMENTAL
Intervention: Elective para-aortic radiotherapy (PART)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Adjuvant whole pelvic radiotherapy (WPRT) alone
Number of subjects: 137
Study: 30545813

Group type: EXPERIMENTAL
Intervention: Mindful eating training (12-week group intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet with mindful eating training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Carbohydrate-restricted diet without mindful eating training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mindful eating training
Number of subjects: 60
Study: 30546043

Group type: EXPERIMENTAL
Intervention: Late AKI
Number of subjects: 2152
Study: 30546947

Group type: EXPERIMENTAL
Intervention: MAGE-A3 vaccination utilizing the oncolytic Maraba virus
Number of subjects: 0
Study: 30546948

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibrutinib in selective adjuvant combinations
Number of subjects: 0
Study: 30546962

Group type: EXPERIMENTAL
Intervention: Zolbetuximab in conjunction with chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zolbetuximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study: 30547094

Group type: EXPERIMENTAL
Intervention: Hippocampal thickness measurement
Number of subjects: 0
Study: 30547379

Group type: EXPERIMENTAL
Intervention: Auto-injector (AI)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Pre-filled syringe (PFS)
Number of subjects: 265
Study: 30547388

Group type: EXPERIMENTAL
Intervention: Mealtime fast-acting insulin aspart (faster aspart)
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Insulin aspart (IAsp) or basal-only insulin therapy
Number of subjects: 1686

Group type: EXPERIMENTAL
Intervention: Mealtime faster aspart
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Insulin comparators
Number of subjects: 1686
Study: 30547830

Group type: EXPERIMENTAL
Intervention: Non-invasive foetal RHD genotyping
Number of subjects: 850

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 850
Study: 30548089

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) status in patients with HFrEF
Number of subjects: 5255

Group type: EXPERIMENTAL
Intervention: Asian women with HFrEF
Number of subjects: 5255

Group type: COMPARATOR
Intervention: Asian men with HFrEF
Number of subjects: 5255